ENDRA Life Sciences Inc. (NDRA)

NASDAQ: NDRA · USD

$4.69

-0.27 (-5.5%)· Recorded snapshot

Market cap	7M
Net income (ttm)	-5.9M
EPS (ttm)	-$5.38
Shares out	1.5M
Volume	10,125
Beta	-0.08

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -5.9M
EPS (ttm): -$5.38
Market cap: 7M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Trzymaj

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-152

P25 n/aP50 n/aP75 n/a

ROIC-94.8

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All NDRA indicators

Market & fundamental data

Available fields

182

Groups with data

Currency

USD

Showing 182 of 182 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001681682
Company name	ENDRA Life Sciences Inc.
Country	United States
Country code	US
CUSIP number	29273B500
Earnings date	2026-11-16
Earnings time	bmo
Employees	11
Employees change	-5
Employees growth	-31.25%
Enterprise value	$5.7M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2007
Industry	Diagnostics & Research
IPO date	2017-05-09
Is primary listing	Yes
Is SPAC	No
ISIN number	US29273B5003
Last 10-K release date	2026-03-31
Last earnings date	2026-08-17
Last refreshed	2026-10-28
Last stock split date	2024-11-07
Last stock split type	Reverse
Market cap	$7M
Market cap category	Nano-Cap
Next earnings date	2026-11-16
Options	No
Price	$4.69
Price currency	USD
Sector	Healthcare
SIC code	3845
Stock price date	2026-10-28
Symbol	NDRA
U.S. state	Michigan
Website	https://endrainc.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-114.75%
FCF / EV yield	-78.98%
FCF yield	-65.07%
Industry forward P/E	30.92x
Industry P/E	50.57x
P/B ratio	1.18x
Price / tangible book value	1.18x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-537,878
Profitable quarters	1
ROA	-77.32%
ROA (5Y)	-86.02%
ROCE	-92.93%
ROE	-152.04%
ROE (5Y)	-199.93%
ROIC	-94.78%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	2
EPS growth years	6
Net income growth quarters	1
Net income growth years	1
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-18,670
Depreciation and amortization	$38,551
EBIT	$-6.6M
EBITDA	$-6.6M
EPS	$-5.38
FCF per share	$-3.23
Financing cash flow	$8.9M
Free cash flow	$-4.8M
Free cash flow minus SBC	$-6M
Investing cash flow	$-332,895
Net cash flow	$3.7M
Net income	$-5.9M
Operating cash flow minus SBC	$-6M
Operating income	$-6.6M
Stock-based compensation	$1.2M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$4.21
Debt / equity	0.07
Long-term assets	$2.4M
Long-term liabilities	$845,936
Net cash (debt)	$1.3M
Net cash / market cap	17.61%
Net cash growth	4.76%
Net debt / equity	-0.21
Piotroski F-Score	2
Property, plant and equipment	$444,255
Shareholders' equity	$6.3M
Tangible book value	$6.3M
Tangible book value per share	$4.21
Total assets	$7.9M
Total cash	$1.7M
Total debt	$429,274
Total liabilities	$1.6M
WACC	3.59%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$5.6M
Current liabilities	$786,578
Current ratio	7.1
Net working capital	$3.2M
Quick ratio	2.21
Working capital	$4.8M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-113.32%
Dividend yield	0%
Shareholder yield	-113.32%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$5.13
1D price change	-5.46%
1M price change	-22.35%
1M total return	-22.35%
1W price change	0.21%
1W total return	0.21%
1Y price change	-11.51%
1Y return CAGR	-11.52%
1Y total return	-11.51%
20-day SMA	$5.22
200-day SMA	$4.80
3M price change	-1.88%
3M total return	-1.88%
3Y price change	-99.72%
3Y return CAGR	-85.96%
3Y total return	-99.72%
50-day SMA	$5.42
50-day SMA vs 200-day SMA	50over200
52-week high	$6.95
52-week high date	2025-11-17
52-week low	$2.96
52-week low date	2026-03-10
5Y price change	-99.99%
5Y return CAGR	-84.61%
5Y total return	-99.99%
6M price change	-2.7%
6M total return	-2.7%
All-time high	$205,800.21
All-time high date	2017-12-26
All-time low	$2.90
All-time low date	2025-05-09
Average true range (ATR)	$0.41
Average volume	15.1K
Beta (1Y)	3.53
Beta (2Y)	1.7
Beta (5Y)	-0.08
Change from 52-week high	-32.52%
Change from 52-week low	58.45%
Change from all-time high	-100%
Change from all-time low	61.72%
Change from open	-5.44%
Day's gap	-0.02%
Dollar volume	$47,486
High price	$5.10
Low price	$4.56
Monthly RSI	31.7
Open price	$4.96
Position in 52-week range	24.07%
Premarket change	-5.26%
Premarket close	$4.96
Premarket price	$4.70
Previous close	$4.96
Price vs 150-day SMA	-8.51%
Price vs 20-day SMA	-10.22%
Price vs 200-day SMA	-2.35%
Price vs 50-day SMA	-13.53%
Relative volume	0.68
RSI	40.4
Sharpe ratio	0.38
Sharpe ratio (3Y)	-0.39
Sharpe ratio (5Y)	-0.64
Sortino ratio	0.62
Sortino ratio (3Y)	-0.6
Sortino ratio (5Y)	-0.97
Volume	10.1K
Weekly RSI	44.78
YTD price change	3.53%
YTD total return	3.53%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1.4M
Float percentage	90.82%
Shares change (QoQ)	106.34%
Shares change (YoY)	113.32%
Shares held by insiders	4.73%
Shares held by institutions	10.24%
Shares outstanding	1.5M
Short % of float	1.77%
Short % of shares	1.61%
Short ratio	0.5 days

Deeper analysis on NDRA

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this NDRA report

Is a complete NDRA research report available?

No complete published report is available for ENDRA Life Sciences Inc. (NDRA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

ENDRA Life Sciences Inc. (NDRA)

Price

Financial snapshot

Fair-value bridge

Latest news · NDRA

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All NDRA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on NDRA

Frequently asked questions